Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Mod Pathol. 2012 Jun;25(6):902-10. doi: 10.1038/modpathol.2011.207. Epub 2012 Mar 30.
Mod Pathol. 2012.
PMID: 22460813
Free article.
An improved method for constructing tissue microarrays from prostate needle biopsy specimens.
McCarthy F, Fletcher A, Dennis N, Cummings C, O'Donnell H, Clark J, Flohr P, Vergis R, Jhavar S, Parker C, Cooper CS.
McCarthy F, et al. Among authors: vergis r.
J Clin Pathol. 2009 Aug;62(8):694-8. doi: 10.1136/jcp.2009.065201.
J Clin Pathol. 2009.
PMID: 19638540
Free PMC article.
Item in Clipboard
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C.
Vergis R, et al.
Lancet Oncol. 2008 Apr;9(4):342-51. doi: 10.1016/S1470-2045(08)70076-7. Epub 2008 Mar 17.
Lancet Oncol. 2008.
PMID: 18343725
Free article.
Item in Clipboard
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.
Vergis R, Corbishley CM, Thomas K, Horwich A, Huddart R, Khoo V, Eeles R, Sydes MR, Cooper CS, Dearnaley D, Parker C.
Vergis R, et al.
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):35-41. doi: 10.1016/j.ijrobp.2009.07.1728. Epub 2010 Jan 21.
Int J Radiat Oncol Biol Phys. 2010.
PMID: 20092961
Clinical Trial.
Item in Clipboard
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators.
Brown JE, et al.
Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13.
Lancet Oncol. 2023.
PMID: 36796394
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite